Nanodroplet oxyGen delivery (NanO2) for ST-elevation myocardial InfarCtion: GNOSTIC

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 25 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

25 Mar 2025 New trial record
04 Mar 2025 According to a NuvOx Pharma media release, Successful completion of the GNOSTIC Trial may lead to a new paradigm in cardioprotection in acute heart attack to improve outcomes in this deadly disease.
04 Mar 2025 According to a NuvOx Pharma media release, Dr. Linda Peterson, Professor of Medicine and of Radiology at Washington University School of Medicine in St Louis, is Principal Investigator of the GNOSTIC Trial. T

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com